Researchers at the Biodesign Institute at Arizona State University have identified more than 30 breast cancer gene targets which could provide a new tool to test a patient's resistance to chemotherapy, according to the Times of India
One of the biggest problems for doctors treating breast cancer is that they have no way of testing for a person's resistance to chemotherapy drugs like tamoxifen. A patient could begin a arduous round of chemotherapy only to find out that they have built up an immunity and will have to switch treatments.
The study tested 500 regulatory proteins, called kinases, in genetic screening against fully sequenced human genes. The kinases are one of the main engines for tumor growth and drug resistance.
With these proteins at hand, the researchers compared gene expression patterns with the cells and were able to identify a group of genes that did not respond to tamoxifen. The team identified 30 kinases that allowed the cells to grow in the presence of the chemo drug, which could prove invaluable in choosing treatment options for patients.
According to BreastCancer.org, there are over 2.5 million breast cancer survivors living in the United States.